drugset / Trial / NCT02133664
Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis
Phase 1/2
Completed
54 enrolled
Oregon Health and Science University
National Multiple Sclerosis Society · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary aim is to collect data to determine the correct effect size on the primary outcome to aid in the design of a larger study: The primary outcome is to determine if lipoic acid and omega-3 fatty acids can improve cognitive function in people with multiple sclerosis that have cognitive dysfunction.
Timeline
- Start
- 2014-06
- Primary completion
- 2016-05
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Omega-3 fatty acids | Unknown | 1.35 g | — |
| Subject | Omega-3 fatty acids | Unknown | 1.95 g | — |
| Subject | alpha-lipoic acid | Small molecule | 1200 mg | — |